These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 4367253)
41. Nitroglycerin revisited: chemistry, biochemistry, interactions. di Carlo FJ Drug Metab Rev; 1975; 4(1):1-38. PubMed ID: 812687 [No Abstract] [Full Text] [Related]
42. Pharmacokinetics in clinical practice. I. Concepts. Gibaldi M; Levy G JAMA; 1976 Apr; 235(17):1864-7. PubMed ID: 946488 [TBL] [Abstract][Full Text] [Related]
45. [Effects of carcinogens and mutagens on nucleic acids. V. On the interaction of DNA with sarcolysin]. Kushner VP; Khodosova IA Tsitologiia; 1968 Oct; 10(10):1313-8. PubMed ID: 5733949 [No Abstract] [Full Text] [Related]
46. [Fundamentals of drug metabolism]. Netter KJ Arzneimittelforschung; 1972 Feb; 22(2):285-92. PubMed ID: 4402072 [No Abstract] [Full Text] [Related]
47. Partitioning phenomena in dosage form and biopharmaceutical design. 3. Some partitioning considerations in drug absorption, distribution, response and elimination. Schumacher GE Am J Hosp Pharm; 1972 Apr; 29(4):339-43. PubMed ID: 5025265 [No Abstract] [Full Text] [Related]
48. [Pharmacokinetics and compartmental analysis]. Grégoire F J Pharm Belg; 1972; 27(5):631-47. PubMed ID: 4660651 [No Abstract] [Full Text] [Related]
49. [Some fundamental concepts of pharmacokinetic practice]. Perrier CV; Griessen M Pharm Acta Helv; 1974; 49(7-8):217-28. PubMed ID: 4462123 [No Abstract] [Full Text] [Related]
50. Cytochrome P-448 and the activation of toxic chemicals and carcinogens. Ioannides C; Lum PY; Parke DV Xenobiotica; 1984; 14(1-2):119-37. PubMed ID: 6719936 [TBL] [Abstract][Full Text] [Related]
51. Intra- and extra-cellular formation of metabolites from chemically reactive species. Gillette JR; Lau SS; Monks TJ Biochem Soc Trans; 1984 Feb; 12(1):4-7. PubMed ID: 6705984 [No Abstract] [Full Text] [Related]
52. Clinical importance of pharmacokinetic and pharmacodynamic drug interactions. Koch-Weser J Neth J Med; 1977; 20(2):59-70. PubMed ID: 325426 [No Abstract] [Full Text] [Related]
53. Mutagenicity and carcinogenicity of mycotoxins: DNA binding as a possible mode of action. Stark AA Annu Rev Microbiol; 1980; 34():235-62. PubMed ID: 7002024 [No Abstract] [Full Text] [Related]
54. Carcinogen-metabolizing enzymes and susceptibility to chemical carcinogenesis. Bartsch H; Aitio A; Camus AM; Malaveille C; Roberfroid M; Vo Thi KO; Sabadie N IARC Sci Publ; 1983; (51):147-56. PubMed ID: 6321342 [No Abstract] [Full Text] [Related]
55. Extramicrosomal drug metabolism. Pütter J Eur J Drug Metab Pharmacokinet; 1979; 4(1):1-7. PubMed ID: 381004 [TBL] [Abstract][Full Text] [Related]
56. Drug distribution and effect. Curry SH J R Coll Physicians Lond; 1970 Jul; 4(4):315-34. PubMed ID: 4948351 [No Abstract] [Full Text] [Related]
57. The problem of chemically reactive metabolites. Gillette JR Drug Metab Rev; 1982; 13(6):941-61. PubMed ID: 6754318 [No Abstract] [Full Text] [Related]
58. Toxic effects of chemicals: difficulties in extrapolating data from animals to man. Garattini S Crit Rev Toxicol; 1985; 16(1):1-29. PubMed ID: 3910353 [TBL] [Abstract][Full Text] [Related]
59. Letter: Renal contribution to drug biotransformation. Kamath BL; Levy G J Pharm Sci; 1974 Aug; 63(8):1342-3. PubMed ID: 4852916 [No Abstract] [Full Text] [Related]
60. Domestication of chemistry by design of safer chemicals: structure-activity relationships. Ariëns EJ Drug Metab Rev; 1984; 15(3):425-504. PubMed ID: 6386409 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]